Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 950-957

  Chen, Fengsheng ^a   Luo, Xi ^a   Zhang, Jinbiao ^a   Lu, Yang ^a,b   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytokeratin 19 fragments; Gefitinib; Non small cell lung cancer; Prognostic factor; Tissue polypeptide specific antigen

Indexed keywords

ANTIGEN; CYTOKERATIN 19 FRAGMENT; GEFITINIB; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CORRELATION ANALYSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 77956912530     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9315-8     Document Type: Article

References (44)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 1 43 66 10.3322/canjclin.57.1.43 17237035
2. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 10.3322/canjclin.55.2.74 15761078
3. CJ Beadsmoore NJ Screaton 2003 Classification, staging and prognosis of lung cancer Eur J Radiol 45 1 8 17 10.1016/S0720-048X(02)00287-5 12499060 1:STN:280:DC%2BD38jjs12ntQ%3D%3D (Pubitemid 36024163)
4. GV Scagliotti F De Marinis M Rinaldi L Crino C Gridelli S Ricci, et al. 2002 Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 21 4285 4291 10.1200/JCO.2002.02.068 12409326 1:CAS:528:DC%2BD38Xpt1CjtLs%3D (Pubitemid 35266288)
5. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 92 98 10.1056/NEJMoa011954 11784875 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D (Pubitemid 34438899)
6. OS Breathnach B Freidlin B Conley MR Green DH Johnson DR Gandara, et al. 2001 Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results J Clin Oncol 19 6 1734 1742 11251004 1:STN:280:DC%2BD3M3gsl2ntw%3D%3D
7. FA Shepherd J Dancey R Ramlau K Mattson R Gralla M O'Rourke, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 10 2095 2103 10811675 1:CAS:528: DC%2BD3cXktVyjsLc%3D
8. E Massarelli F Andre DD Liu JJ Lee M Wolf A Fandi, et al. 2003 A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer Lung Cancer 39 1 55 61 10.1016/S0169-5002(02)00308-2 12499095 1:STN:280:DC%2BD38jjslaqtA%3D%3D (Pubitemid 36020295)
9. V Rusch J Baselga C Cordon-Cardo J Orazem M Zaman S Hoda, et al. 1993 Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Res 53 10 Suppl 2379 2385 7683573 1:CAS:528:DyaK3sXkvFamtLg%3D
10. N Thatcher A Chang P Parikh PJ Rodrigues T Ciuleanu J von Pawel, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 9496 1527 1537 10.1016/S0140-6736(05)67625-8 16257339 1:CAS:528:DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
11. H Jiang 2009 Overview of gefitinib in non-small cell lung cancer: an Asian perspective Jpn J Clin Oncol 39 3 137 150 10.1093/jjco/hyn139 19088154
12. K Park K Goto 2006 A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer Curr Med Res Opin 22 3 561 573 10.1185/030079906X89847 16574039 1:CAS:528:DC%2BD28XjvV2htLo%3D
13. DG Pfister DH Johnson CG Azzoli W Sause TJ Smith Jr S Baker, et al. 2004 American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2 330 353 10.1200/JCO.2004.09.053 14691125 (Pubitemid 41095099)
14. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard, et al. 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 12 2237 2246 10.1200/JCO.2003.10.038 12748244 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
15. FA Shepherd PJ Rodrigues T Ciuleanu EH Tan V Hirsh S Thongprasert, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 123 132 10.1056/NEJMoa050753 16014882 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
16. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2129 2139 10.1056/NEJMoa040938 15118073 1:CAS:528: DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
17. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 10.1126/science.1099314 15118125 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
18. K Sugio H Uramoto T Onitsuka M Mizukami Y Ichiki M Sugaya, et al. 2009 Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations Lung Cancer 64 3 314 318 10.1016/j.lungcan.2008.09.010 18992959
19. H Bai L Mao HS Wang J Zhao L Yang TT An, et al. 2009 Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 16 2653 2659 10.1200/JCO.2008.17.3930 19414683 1:CAS:528:DC%2BD1MXnslWit7c%3D
20. V Barak H Goike KW Panaretakis R Einarsson 2004 Clinical utility of cytokeratins as tumor markers Clin Biochem 37 7 529 540 10.1016/j.clinbiochem. 2004.05.009 15234234 1:CAS:528:DC%2BD2cXltl2gtLc%3D (Pubitemid 38845016)
21. G Buccheri D Ferrigno 2001 Lung tumor markers of cytokeratin origin: an overview Lung Cancer 34 Suppl 2 S65 S69 10.1016/S0169-5002(01)00347-6 11720744
22. S Green GR Weiss 1992 Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 10 4 239 253 10.1007/BF00944177 1487397 1:STN:280:DyaK3s7jvV2jsw%3D%3D (Pubitemid 23008970)
23. CH Chiu YN Shih CM Tsai JL Liou YM Chen RP Perng 2007 Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib Lung Cancer 57 2 213 221 10.1016/j.lungcan.2007.02.016 17449138 (Pubitemid 47043179)
24. T Okamoto T Nakamura J Ikeda R Maruyama F Shoji T Miyake, et al. 2005 Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer Eur J Cancer 41 9 1286 1290 10.1016/j.ejca.2005.03.011 15939264 1:CAS:528:DC%2BD2MXltFCktrY%3D (Pubitemid 40813004)
25. A Chang P Parikh S Thongprasert EH Tan RP Perng D Ganzon, et al. 2006 Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study J Thorac Oncol 1 8 847 855 10.1097/01243894-200610000-00014 17409969
26. ZZ Guan L Zhang LY Li GL Jiang XY Liu DT Chu, et al. 2005 Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial Ai Zheng 24 8 980 984 16086877
27. KS Kim JY Jeong YC Kim KJ Na YH Kim SJ Ahn, et al. 2005 Predictors of the response to gefitinib in refractory non-small cell lung cancer Clin Cancer Res 11 6 2244 2251 10.1158/1078-0432.CCR-04-2081 15788673 1:CAS:528: DC%2BD2MXisFaju74%3D (Pubitemid 40490183)
28. J Park BB Park JY Kim SH Lee SI Lee HY Kim, et al. 2004 Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer Clin Cancer Res 10 13 4383 4388 10.1158/1078-0432. CCR-04-0189 15240526 1:CAS:528:DC%2BD2cXlsVWltr8%3D (Pubitemid 38878878)
29. MZ Wang W Zhong L Zhang LY Li SL Wang JR Li, et al. 2008 Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 30 3 221 224 18756941 1:CAS:528:DC%2BD1cXntVSrsLs%3D
30. YL Wu WZ Zhong LY Li XT Zhang L Zhang CC Zhou, et al. 2007 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China J Thorac Oncol 2 5 430 439 10.1097/01.JTO.0000268677.87496.4c 17473659 (Pubitemid 47181698)
31. A Marchetti C Martella L Felicioni F Barassi S Salvatore A Chella, et al. 2005 EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 4 857 865 10.1200/JCO.2005.08.043 15681531 1:CAS:528:DC%2BD2MXitVKit7o%3D (Pubitemid 46224186)
32. H Shigematsu L Lin T Takahashi M Nomura M Suzuki II Wistuba, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 5 339 346 10.1093/jnci/dji055 15741570 1:CAS:528:DC%2BD2MXitV2jsb4%3D (Pubitemid 40425952)
33. A Ardizzoni MA Cafferata M Tiseo R Filiberti P Marroni F Grossi, et al. 2006 Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non small cell lung cancer Cancer 107 12 2842 2849 10.1002/cncr.22330 17103443 1:CAS:528:DC%2BD2sXovF2isg%3D%3D (Pubitemid 44937038)
34. B Nisman G Amir J Lafair N Heching O Lyass T Peretz, et al. 1999 Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer Anticancer Res 19 4C 3549 3552 10629651 1:CAS:528:DC%2BD3cXktlOm
35. B Nisman J Lafair N Heching O Lyass M Baras T Peretz, et al. 1998 Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in non small cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82 10 1850 1859 10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R 9587116 1:STN:280:DyaK1c3ks1GnsQ%3D%3D (Pubitemid 28208639)
36. JL Pujol J Grenier E Parrat M Lehmann T Lafontaine X Quantin, et al. 1996 Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS Am J Respir Crit Care Med 154 3 Pt 1 725 733 8810612 1:STN:280: DyaK28vgs1CqtQ%3D%3D
37. V Barak B Nisman I Roisman A Hubert B Burde T Peretz 1994 TPS in evaluation of response to taxol and interferon therapy in breast cancer patients J Tumor Marker Oncol 8 89
38. V Barak B Nisman IHF Roisman L Baider A Kaplan, et al. 1997 TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons J Tumor Marker Oncol 12 4 17 26
39. F Barlesi C Tchouhadjian C Doddoli JP Torre P Astoul JP Kleisbauer 2005 CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy Br J Cancer 92 1 13 14 10.1038/sj.bjc.6602296 15597098 1:CAS:528:DC%2BD2MXhtFSjs70%3D (Pubitemid 40188428)
40. A Van Der Gaast TC Kok GS Kho BG Blijenberg TA Splinter 1995 Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer Eur J Cancer 31A 11 1790 1793 8541102
41. W Ebert M Hoppe T Muley P Drings 1997 Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE Anticancer Res 17 4B 2875 2878 9329552 1:STN:280:DyaK2svntVWgtw%3D%3D
42. S Holdenrieder P Stieber J Von Pawel H Raith D Nagel K Feldmann, et al. 2006 Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments Ann N Y Acad Sci 1075 244 257 10.1196/annals.1368.033 17108218 1:CAS:528: DC%2BD28XhtFCqsLfJ (Pubitemid 44532791)
43. S Holdenrieder J von Pawel E Dankelmann T Duell B Faderl A Markus, et al. 2009 Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer Lung Cancer 63 1 128 135 10.1016/j.lungcan.2008.05.001 18571761
44. S Holdenrieder J von Pawel E Dankelmann T Duell B Faderl A Markus, et al. 2008 Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer Clin Cancer Res 14 23 7813 7821 10.1158/1078-0432.CCR-08-0678 19047109 1:CAS:528:DC%2BD1cXhsVegtrfL